Sleep apnoea drug developer Apnimed has completed its IPO on the Nasdaq, following the trend of the year for biotechs by comfortably exceeding its fundraising target. The Cambridge, Massachusetts-based company expects to make around $192 million from the listing, well above its expectation of $150 million, with the sale of 12 million shares at $16, the top of its anticipated range. An FDA decision is due in February and, if approved, Oxnimbi could become the first broadly usable treatment for obstructive sleep apnoea (OSA), which affects millions of people in the US. Meanwhile, three other biotechs in the Nasdaq IPO queue – Braveheart Bio, Attovia, and Vogenx – have also set terms for their market debuts this week. Finally, Vogenx has set terms for its IPO at 6.3 million shares at an offer price of $11 to $13, targeting $75 million in proceeds for the development of a small-molecule SGLT1 inhibitor, mizagliflozin, which it licenses from Japan's Kissei Pharma.